### Introduction

**Introduction to the Eleventh Conference on Cancer Therapy with Antibodies and Immunoconjugates**
David M. Goldenberg

---

### Session I: New Antibodies and Approaches

**Cell Cycle Disturbances and Mitotic Catastrophes in HeLa Hep2 Cells following 2.5 to 10 Gy of Ionizing Radiation**
David Eriksson, Per-Olov Löfroth, Lennart Johansson, Katrine Åhlström Riklund, and Torgny Stigbrand

**The La Autoantigen Is a Malignancy-Associated Cell Death Target That Is Induced by DNA-Damaging Drugs**
Fares Al-Ejeh, Jocelyn M. Darby, and Michael P. Brown

**In vivo Targeting of Dead Tumor Cells in a Murine Tumor Model Using a Monoclonal Antibody Specific for the La Autoantigen**

**Bortezomib Sensitizes Non–Hodgkin’s Lymphoma Cells to Apoptosis Induced by Antibodies to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL) Receptors TRAIL-R1 and Trail-R2**
Mitchell R. Smith, Fang Jin, and Indira Joshi

**Combination Treatment with TRA-8 Anti–Death Receptor 5 Antibody and CPT-11 Induces Tumor Regression in an Orthotopic Model of Pancreatic Cancer**
Leo Christopher DeRosier, Donald J. Buchsbaum, Patsy G. Oliver, Zhi-Qiang Huang, Jeffrey C. Sellers, William E. Grizzle, Tong Zhou, Kurt R. Zinn, Joshua W. Long, and Selwyn M. Vickers

**Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy**
Hagop Youssoufian, Daniel J. Hicklin, and Eric K. Rowinsky

**IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor**

**CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms**
Rhona Stein, M. Jules Matess, Thomas M. Cardillo, Hans J. Hansen, Chien-Hsing Chang, Jack Burton, Serengulam Govindan, and David M. Goldenberg

**A Divalent Hapten-Peptide Induces Apoptosis in Human Non–Hodgkin Lymphoma Cell Lines Targeted by Anti-CD20 × Anti-Hapten Bispecific Antibodies**

---

### Session II: Pretargeting

**Improved Tumor Targeting and Decreased Normal Tissue Accumulation through Extracorporeal Affinity Adsorption in a Two-Step Pretargeting Strategy**
Linda Mårtensson, Rune Nilsson, Tomas Ohiłsson, Hans-Olov Sjögren, Sven-Erik Strand, and Jan Tennvall

The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retained Bioactivity
Chien-Hsing Chang, Edmund A. Rossi, and David M. Goldenberg

Pathology Underrates Colon Cancer Extranodal and Nodal Metastases; Ex vivo Radioimmunodetection Helps Staging

Pretargeted Radioimmunotherapy for B-Cell Lymphomas
Damian J. Green, John M. Pagel, Anastasia Pantelias, Nathan Hedin, Yukang Lin, D. Scott Wilbur, Ajay Gopal, Donald K. Hamlin, and Oliver W. Press

Radioimmunotherapy with α-Particle–Emitting 213Bi-C-Functionalized trans-Cyclohexyl-Diethylentriaminepentaacetic Acid–Humanized 3S193 Is Enhanced by Combination with Paclitaxel Chemotherapy
Marcus P. Kelly, Fook T. Lee, Kiki Tahtis, Fiona E. Smyth, Martin W. Brechbiel, and Andrew M. Scott

Binding Activities and Antitumor Properties of a New Mouse/Human Chimeric Antibody Specific for GD2 Ganglioside Antigen

Selective High-Affinity Ligand Antibody Mimics for Cancer Diagnosis and Therapy: Initial Application to Lymphoma/Leukemia
Rod Balhorn, Saphon Hok, Patricia A. Burke, Felice C. Lightstone, Monique Cosman, Adam Zemla, Gary Mirick, Julie Perkins, Arutelsvan Natarajan, Michele Corzett, Sally I. DeNardo, Huguette Albrecht, Jeff P. Gregg, and Gerry L. DeNardo

Comparative Evaluation of Capsular Polysaccharide-Specific IgM and IgG Antibodies and F(ab')₂ and Fab Fragments as Delivery Vehicles for Radioimmunotherapy of Fungal Infection
Ekaterina Dadachova, Ruth A. Bryan, Xianchun Huang, Geraldina Ortiz, Tiffany Moadel, and Arturo Casadevall

Phase I to III Trials of Anti–B Cell Therapy in Non–Hodgkin’s Lymphoma
Peter Martin, Richard R. Furman, Morton Coleman, and John P. Leonard

Brief Overview of Preclinical and Clinical Studies in the Development of Intraperitoneal Radioimmunotherapy for Ovarian Cancer
Ruby F. Meredith, Donald J. Buchsbaum, Ronald D. Alvarez, and Albert F. LoBuglio

Intraoperative Avidination for Radionuclide Therapy: A Prospective New Development to Accelerate Radiotherapy in Breast Cancer
Giovanni Paganeli, Mahila Ferrari, Laura Ravasi, Marta Cremonesi, Concetta De Cicco, Viviana Galimberti, Gregory B. Sivolapenko, Alberto Luini, Rita De Santis, Laura Lavinia Travaini, Maurizio Fiorenza, Marco Chinol, Stefano Papi, Claudio Zanna, Paolo Carminati, and Umberto Veronesi
A Phase I Study of 90Yttrium-Ibritumomab-Tiuxetan in Children and Adolescents with Relapsed/Refractory CD20 Positive Non–Hodgkin’s Lymphoma: A Children’s Oncology Group Study
Erin Cooney-Qualter, Mark Kralio, Anne Angiolillo, Rashid A. Fawwaz, Gregory Wiseman, Lauren Harrison, Virginia Kohl, Peter C. Adamson, Janet Ayello, Carmella vande Ven, Sherrie L. Perkins, and Mitchell S. Cairo

About the Cover
A number of different topics were discussed at the 11th Conference. A new human antibody to the insulin-growth factor I receptor (IGF-IR), which can block downstream MAPK and PI3/KT pathways, was presented (A, Rowinsky et al. on page 5549s in this issue). This antibody shows promising anti-tumor activity in animal models alone and in combination with chemotherapy. Innovative antibody constructs, including selective high affinity ligand (SHAL) antibody mimics targeting HLA-DR10 (B, Balhorn et al. on page 5621s in this issue), and a new platform for preparing multivalent, multifunctional bispecific antibodies using a newly described Dock and Lock procedure (C, Chang et al. on page 5586s in this issue) were presented. Microscopic human colon cancer as small as 0.3 mm were disclosed in the lungs using microPET imaging, and autoradiography illustrated the selective uptake in the metastatic tumors (D, Sharkey et al. on page 5577s in this issue). Multivalent bispecific antibodies prepared by the Dock and Lock procedure were used in a pretargeting setting for targeting radionuclides (E, Sharkey et al. on page 5577s in this issue).